Rani Therapeutics Holdings (RANI) Amortizatization of Intangibles (2022 - 2026)
Rani Therapeutics Holdings' (RANI) quarterly Amortizatization of Intangibles came in at $244000.0 in Q1 2026, up 62.67% year-on-year from $150000.0 in Q1 2025, and up 103.33% quarter-over-quarter from $120000.0 in Q4 2025.
Rani Therapeutics Holdings (RANI) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Amortizatization of Intangibles history runs 5 years deep, the most recent figure standing at $244000.0 for Q1 2026.
- On a quarterly basis, Amortizatization of Intangibles rose 62.67% year-over-year to $244000.0 in Q1 2026; TTM through Mar 2026 was $372000.0, a 64.81% decrease from a year earlier, with the FY2025 full-year figure at $278000.0, down 77.71% from the prior year.
- Amortizatization of Intangibles grew to $244000.0 in Q1 2026 per RANI's latest filing, from $120000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $699000.0 in Q1 2023 and bottomed at $8000.0 in Q2 2025.
- The 5-year median for Amortizatization of Intangibles is $308500.0 (2024), against an average of $352571.4.
- Across the five-year window, Amortizatization of Intangibles jumped 190.0% in 2023 and tumbled 97.24% in 2025, its largest moves.
- Year by year, Amortizatization of Intangibles stood at $641000.0 in 2022, then dropped by 27.46% to $465000.0 in 2023, then slumped by 33.98% to $307000.0 in 2024, then plunged by 60.91% to $120000.0 in 2025, then soared by 103.33% to $244000.0 in 2026.
- Per Business Quant, the three latest RANI Amortizatization of Intangibles figures stand at $244000.0 (Q1 2026), $120000.0 (Q4 2025), and $8000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Rani Therapeutics Holdings | 144.81 Mn | 144.81 Mn | - | 244,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 244,000.00 |
| Mar 31, 2026 | 244,000.00 |
| Dec 31, 2025 | 120,000.00 |
| Dec 31, 2025 | 120,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 307,000.00 |
| Dec 31, 2024 | 307,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Sep 30, 2024 | 310,000.00 |
| Jun 30, 2024 | 290,000.00 |
| Jun 30, 2024 | 290,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Mar 31, 2024 | 340,000.00 |
| Dec 31, 2023 | 465,000.00 |
| Dec 31, 2023 | 465,000.00 |
| Sep 30, 2023 | 609,000.00 |
| Sep 30, 2023 | 609,000.00 |